A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis

Inclusion Criteria:

• Have had an established diagnosis of UC of ≥3 months in duration before baseline.

• Have moderately to severely active UC as assessed by the UC disease activity score.

• Have an inadequate response to, loss of response to, or intolerance to at least oneconventional medication (including corticosteroids) or one advanced therapy (including biologics, Janus Kinase (JAK) inhibitors, or sphingosine-1-phosphate (S1P) immunomodulators).

• Are on a stable dose of certain oral UC medications (including corticosteroids).

• Must meet contraception requirements.

Exclusion Criteria:

• Have received anti-interleukin (IL)-23p19 or anti-IL-12p40 antibodies in the past.

• Have experienced a thrombotic event within 24 weeks before baseline.

• Have a current diagnosis of Crohn's Disease or certain other inflammatorygastrointestinal diseases.

• Have had certain abdominal surgeries within the past 3 months or are likely torequire surgery for UC during the study.

• Have a history of certain adenomas, dysplasia's, or malignancies.